8-KLeadership ChangesRegulation FDExhibits & Filings

MCKESSON CORP 8-K Report, Executive Changes (Jun 3, 2024)

Filed June 3, 2024For Securities:MCK

Summary

McKesson Corporation (MCK) announced a board composition change through an 8-K filing. The company has elected Deborah Dunsire, M.D., to its Board of Directors, effective June 3, 2024. Dr. Dunsire brings extensive experience in the biopharmaceutical and oncology sectors, having previously served as CEO of H. Lundbeck A/S and holding various leadership roles in other pharmaceutical companies. Her appointment is expected to enhance the Board's expertise in relevant industries. In addition, McKesson disclosed that two current directors, Linda Mantia and Susan R. Salka, will not be standing for re-election at the upcoming 2024 annual meeting of shareholders. Their terms will expire at that meeting. These changes signal a refresh in the Board's composition, bringing in new strategic perspectives while transitioning out existing members.

Key Highlights

  • 1Election of Deborah Dunsire, M.D., to the Board of Directors, effective June 3, 2024.
  • 2Appointment of Dr. Dunsire to the Compensation and Talent Committee and Finance Committee.
  • 3Dr. Dunsire possesses over 30 years of leadership experience in the biopharmaceutical, oncology, and specialty industries.
  • 4Prior experience of Dr. Dunsire includes serving as CEO of H. Lundbeck A/S and executive roles at other major pharmaceutical firms.
  • 5Linda Mantia will not be standing for re-election at the 2024 annual meeting.
  • 6Susan R. Salka will not be standing for re-election at the 2024 annual meeting.
  • 7The company issued a news release on June 3, 2024, to announce these board changes.

Frequently Asked Questions

This 8-K filing primarily announces changes to McKesson Corporation's Board of Directors, including the election of a new director and the departure of two existing directors at the upcoming annual meeting.

Dr. Deborah Dunsire is a seasoned executive with over 30 years of experience in the biopharmaceutical and oncology sectors. Her notable past roles include serving as president and chief executive officer of H. Lundbeck A/S and holding senior leadership positions at other pharmaceutical companies like XTuit Pharmaceuticals and Millennium: The Takeda Oncology Company.

Linda Mantia and Susan R. Salka will not be standing for re-election at McKesson Corporation's 2024 annual meeting of shareholders, and their terms will expire at that meeting.

While her appointment to the Compensation and Talent Committee and Finance Committee suggests involvement in key governance areas, the filing itself does not explicitly detail any immediate shifts in strategic direction. However, her extensive industry experience may inform future decision-making.